Overcoming TKI resistance in fusion-driven NSCLC: New generation inhibitors and rationale for combination strategies

During the last several years, multiple gene rearrangements with oncogenic potential have been described in NSCLC, identifying specific clinic-pathological subgroups of patients that benefit from a targeted therapeutic approach, including anaplastic lymphoma kinase (ALK), c-ros protooncogene 1 (ROS1...

Full description

Autores:

Russo, Alessandro
Cardona, Andrés F.
Caglevic, Christian
Manca, Paolo
Ruiz Patiño, Alejandro
Arrieta, Oscar
Rolfo, Christian

Tipo de recurso:

Article of journal

Fecha de publicación:

2020

Institución:

Universidad El Bosque

Repositorio:

Repositorio U. El Bosque

Idioma:

eng

OAI Identifier:

oai:repositorio.unbosque.edu.co:20.500.12495/5891

Acceso en línea:

http://hdl.handle.net/20.500.12495/5891
https://doi.org/10.21037/TLCR-2019-CNSCLC-06

Palabra clave:

Anaplastic lymphoma kinase (ALK)
REarranged during Transfection (RET)
C-ros protooncogene 1 (ROS1)
Neurotrophic tyrosine receptor kinases (NTRK)
Acquired resistance

Rights

openAccess

License

Attribution-NonCommercial-NoDerivatives 4.0 Internacional